Sign in
Taking people in United StatesPhase 3

Tests D07001 capsules with capecitabine in advanced biliary tract cancer

Tests D07001 capsules plus capecitabine against placebo in adults with advanced bile duct cancer.

Key facts

Who runs it
InnoPharmax Inc.
Where
Cleveland, Dallas, Miami Beach, and Tucson, United StatesSee the 4 sitesAlso in 1 other country, 1 site
Trial code
Registry title
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Status
Recruiting
Phase
Phase 3
People taking part
240 people, planned
Started
9 Jun 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • D07001-Softgel Capsules
  • Placebo
  • Capecitabine
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced biliary tract cancer that cannot be removed by surgery, after earlier chemotherapy has stopped working. It tests D07001 capsules or placebo together with capecitabine.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Biliary tract cancer (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma) that cannot be removed by surgery, is locally advanced or has spread, with measurable disease. ECOG performance status 0-2 and life expectancy of at least 12 weeks.
Earlier treatment
Gemcitabine plus cisplatin-based chemotherapy has failed. FOLFOX has failed or been refused, or irinotecan plus fluorouracil-based chemotherapy has failed. People whose tumours carry certain markers can join without FOLFOX if targeted therapy was used until progression or intolerance. More than 14 days since the last chemotherapy or targeted therapy.
Biomarker or test result
No marker is needed for most people. For joining without prior FOLFOX, the tumour must show FGFR aberrations, MSI/dMMR, high tumour mutation burden, or IDH, BRAF, HER2, NTRK, RET or KRAS G12C changes.

Main reasons for not taking part

  • Another active cancer in the past 2 years (with few exceptions)
  • Brain or leptomeningeal metastases
  • Positive HIV antibody, or active hepatitis B or C with detectable virus
  • Severe reaction to capecitabine or fluoropyrimidine drugs
  • Stomach or bowel disease or surgery that would block absorption of an oral drug

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Provide written informed consent prior to any study procedures and agree to adhere to all protocol requirements
  • Participant aged at least 18 years at the time of consent
  • Participant has histopathological or cytologic diagnosis of unresectable, locally advanced or metastatic BTC (cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma)
  • Participant has measurable disease as assessed by central review by RECIST v1.1
  • Participant must have failed on a gemcitabine + cisplatin-based chemotherapy, regardless of whether an immune checkpoint inhibitor, such as durvalumab or pembrolizumab, or S-1 (tegafur, gimeracil, and oteracil potassium), was also administered. Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern. Participants also have failed (disease progression or intolerance) on, or refused FOLFOX chemotherapy, including modified FOLFOX variants, or failed on irinotecan + fluorouracil-based chemotherapy
  • Participants with tumors expressing the following biomarkers may be enrolled even if they have not previously received FOLFOX but have received appropriate targeted therapies until disease progression or intolerance: fibroblast growth factor receptors (FGFR) aberrations, microsatellite instability biomarker/deficient DNA mismatch repair, Tumor Mutation Burden-high, or mutations in isocitrate dehydrogenase, BRAF, HER2, NTRK, RET, or KRAS G12C
  • Participant has ECOG PS of 0-2
  • Participant's life expectancy is ≥12 weeks
  • Participant has adequate bone marrow function, demonstrated by:; Absolute neutrophil count ≥1500 cell/mm3; Platelet count ≥85,000 cells/mm3; Hemoglobin ≥9 g/dL
  • Participant has adequate liver function, demonstrated by:; Aspartate transaminase and alanine transaminase ≤2.5 × upper limit of normal (ULN), or ≤5.0 × ULN in the case of liver lesions; Total bilirubin ≤1.5 × ULN; Albumin ≥3.0 g/dL; International normalized ratio <1.5
  • Participant has adequate renal function, demonstrated by creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault formula or estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 by the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine equation
  • No clinically significant abnormalities in coagulation results
  • Participant is eligible to participate if not pregnant (as demonstrated by serum pregnancy testing at Screening), not breastfeeding, and at least 1 of the following conditions applies:; Not of childbearing potential (CBP). Participants of non-childbearing potential are defined as those with functioning ovaries with a documented history of tubal ligation or hysterectomy or who are postmenopausal, as defined by 12 months of spontaneous amenorrhea with an appropriate clinical profile, e.g., age appropriate, >45 years, in the absence of hormone replacement therapy. If necessary, a blood sample for follicle stimulating hormone will be obtained to confirm postmenopausal status; A participant of CBP who is sexually active with a partner who could impregnate them agrees to use a highly effective form of contraception during the study and for at least 6 months after the EOS intervention
  • Participants with partners of childbearing potential whom they could impregnate must agree to use contraception during the study and for 3 months after the EOS intervention
  • Participants who are able to donate sperm must refrain from sperm donation during the study and for 3 months after the EOS intervention
  • Participant is willing to comply with the protocol-required visit schedule and visit requirements
  • More than 14 days have elapsed between the participant completing a prior line of chemotherapy or targeted therapy, and enrollment. More than 28 days have elapsed between the participant receiving concurrent radiotherapy (CCRT) and enrollment

Who cannot take part

  • Participant has a diagnosis of active malignancy other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent
  • Participant discontinued prior gemcitabine due to pulmonary or hepatic toxicity or hemolytic uremic syndrome, hypersensitivity, allergic reaction, or intolerance
  • Participant had a prior unanticipated severe reaction to capecitabine or metabolites or to fluoropyrimidine therapy
  • Participant received treatment with brivudine, sorivudine, or its chemically related analogs ≤28 days prior to the date of enrollment
  • Participant is currently receiving flucytosine treatment
  • Participant has residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted)
  • Participant has any gastrointestinal disorder or prior gastrointestinal surgery that would significantly impede absorption of an oral agent, such as gastrectomy, Crohn's disease, ulcerative colitis, or short gut syndrome
  • Participant had major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days
  • Participant has received an investigational agent within 28 days of enrollment
  • Has positive human immunodeficiency virus antibody
  • Participant has received yellow fever vaccine or other live attenuated vaccine(s) within the 4 weeks before Screening
  • Participant has any active disease or condition that would not permit compliance with the protocol
  • Participant has clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, New York Heart Association Grade 2 or greater), or uncontrolled serious cardiac arrhythmia
  • Participant has documented cerebrovascular disease
  • Participant has a seizure disorder not controlled with medication (based on Investigator's decision)
  • Participant has an uncontrolled active viral, bacterial, or systemic fungal infection
  • Participants with positive hepatitis B surface antigen (HBsAg) or positive hepatitis C virus antibody (anti-HCV) and detectable hepatitis B virus (HBV) DNA ≥2000 copies/mL or hepatitis C virus (HCV) RNA above the institutional lower limit of quantification are excluded. Participants with resolved HBV infection (negative HBsAg and positive hepatitis B core antibody [anti-HBc]) are eligible if HBV DNA is <2000 copies/mL. Participants with positive anti-HCV antibody must have completed curative antiviral therapy and have undetectable HCV RNA by PCR to be eligible
  • Participant has a history of drug or alcohol abuse within the year before signing the informed consent form
  • Participant has any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in or compliance with the clinical trial
  • Participant has known brain or leptomeningeal metastases

Where in United States

Also in 1 other country, 1 site

  • University Hospital Cleveland Medical CenterCleveland, United StatesContact: Amit MahipalTaking people
  • Texas OncologyDallas, United StatesContact: Christine TerracianoNot yet recruiting
  • Mount Sinai Medical CenterMiami Beach, United StatesContact: Yvonne Enriquez NunezTaking people
  • The University of Arizona Cancer CenterTucson, United StatesContact: Prisca ZimmermanTaking people

About the trial

What the trial wants to find out

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).

Read full original descriptionShow less

Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.

The 3 groups in the trial

  • D07001-Softgel Capsules 60 mg + CapecitabineTreatment being tested

    * D07001-softgel capsules, 60 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle) * Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

    Treatment: D07001-Softgel Capsules and Capecitabine

  • D07001-Softgel Capsules 100 mg + CapecitabineTreatment being tested

    * D07001-softgel capsules, 100 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle) * Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

    Treatment: D07001-Softgel Capsules and Capecitabine

  • Placebo + CapecitabinePlacebo, for comparison

    * Placebo, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle) * Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

    Treatment: Placebo and Capecitabine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens
Plain-language title
Tests D07001 capsules with capecitabine in advanced biliary tract cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026